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Abstract: Sporadic Creutzfeldt-Jakob disease (sCJD) is the commonest form of human 
prion diseases, accounting for about 85% of all cases. Current criteria for intra vitam 
diagnosis include a distinct phenotype, periodic sharp and slow-wave complexes at 
electroencephalography (EEG), and a positive 14-3-3-protein assay in the cerebrospinal 
fluid (CSF). In sCJD, the disease phenotype may vary, depending upon the genotype at 
codon 129 of the prion protein gene (PRNP), a site of a common methionine/valine 
polymorphism, and two distinct conformers of the pathological prion protein. Based on the 
combination of these molecular determinants, six different sCJD subtypes are recognized, 
each with distinctive clinical and pathologic phenotypes. We analyzed CSF samples from 
127 subjects with definite sCJD to assess the diagnostic value of 14-3-3 protein, total tau 
protein, phosphorylated181 tau, and amyloid beta (Aβ peptide 1-42, either alone or in 
combination. While the 14-3-3 assay and tau protein levels were the most sensitive 
indicators of sCJD, the highest sensitivity, specificity and positive predictive value were 
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obtained when all the above markers were combined. The latter approach also allowed a 
reliable differential diagnosis with other neurodegenerative dementias. 
Keywords:  sporadic Creutzfeldt-Jakob disease; 14-3-3 protein; tau protein; amyloid   
beta peptide 
 
1. Introduction  
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal neurodegenerative 
disorders of human and animals, occurring as sporadic, genetic and iatrogenic forms [1]. The crucial 
event in the pathogenesis of TSEs is the conformational conversion of the cellular prion protein, or 
PrP
C, into PrP
Sc, a self-propagating protease-resistant isoform. Distinct sites of endogenous or 
exogenous PrP
Sc proteolytic cleavage, generating a core fragment named PrP27-30, characterize 
different prion strains [2,3]. Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human 
TSE, accounts for nearly 85% of all human prion diseases and has an annual incidence of 1–2 cases 
per million. After its recognition in 1922, different clinical subtypes have been described based on 
signs and symptoms at presentation, age at onset, survival time, and diagnostic
 test results. Clinical 
forms of sCJD include the myoclonic or ‘classic’ sCJD, the Heidenhain’s variant,
 the cerebellar or 
ataxic Oppenheimer-Brownell variant, the thalamic and panencephalopathic subtypes. Over the last 
two decades, it has been assessed that the remarkable heterogeneity of sCJD phenotypes is influenced 
by the conformation of PrP
Sc (type 1 or type 2 PrP27-30) and by the polymorphic codon 129 of the 
prion protein gene (PRNP), a site of methionine (M)/valine (V) polymorphism. Currently, a sextet of 
molecular subtypes of sCJD are recognized, named MM1, MV1, VV1, MM2, MV2 and VV2 [4]. 
A definite diagnosis of sCJD is obtained following the demonstration of the pathologic prion 
isoform in brain tissues; possible or probable sCJD is defined on the basis of clinical features, periodic 
sharp and slow waves at electroencephalography (EEG), altered signal at brain MRI, and a positive  
14-3-3 protein assay in the cerebrospinal fluid (CSF) [5,6]. 
A number of studies devoted to CSF analysis in sCJD and other neurodegenerative conditions have 
assessed the diagnostic sensitivity and specificity of different surrogate markers indicative of neuronal 
degeneration or glial cell activation, including 14-3-3 protein, tau protein, phosphorylated tau, S100 
protein, neuronal specific enolase, and amyloid-β (Aβ)1-42, either alone or in combination [7–11]. The 
best investigated CSF markers, namely 14-3-3 proteins, are a group of cytosolic polypeptides, which 
are released in the CSF in disorders other than sCJD, encompassing stroke, infections, inflammatory 
events, epileptic seizures, and toxic-metabolic conditions [12–14]. Despite this apparent lack of 
specificity, it has been shown that within the appropriate clinical setting, a positive 14-3-3 assay may 
provide a diagnostic sensitivity and specificity of nearly 95–98% in sCJD [12,15]. The usefulness of 
the 14-3-3 assay is particularly evident in the differential diagnosis of rapidly progressive dementias 
(RPD) [16,17], especially when combined with quantification of tau protein, a microtubule-binding 
polypeptide, highly expressed in neurons and their axonal extensions [18–20]. 
Aim of the present study was to determine the diagnostic value of “neurodegeneration CSF 
markers” in sCJD. Given the wide phenotypic variability encountered in distinct sCJD subtypes, we Int. J. Mol. Sci. 2011, 12                 
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retrospectively assessed the diagnostic value of CSF markers, either within distinct molecular subtypes 
or in comparison to other dementias. Therefore, we evaluated 14-3-3 protein as well as CSF levels of 
tau, phosphotau181 and Aβ1-42 in 127 cases of definite sCJD, 5 subjects with familial CJD (fCJD),  
7 patients clinically diagnosed with Alzheimer’s disease (AD), and 15 patients with frontotemporal 
dementia (FTD). We assessed the utility and the diagnostic value of each single marker as well as the 
combination of different markers. 
2. Materials and Methods  
2.1. CSF and Patients  
We studied CSF samples from 127 subjects with definite sCJD cases and 5 patients with fCJD  
(3 subjects carrying E200K and 2 V210I mutations). Samples were collected during the period January 
1999 through December 2010, from individual undergoing lumbar puncture for diagnostic purposes.  
A clinical history of the current and past illnesses was obtained, as well as results of EEG and brain 
MRI. Control groups consisted of 7 subjects with AD, 15 with FTD, 4 with herpes encephalitis, and 15 
non-neurological patients. The study was done in accordance with the current revision of Declaration 
of Helsinki and the Good Clinical Practice guidelines. A written consent for all diagnostic procedures, 
including genetic studies, was obtained. 
2.2. PRNP Codon 129 Genotype, PrP
Sc Typing and Molecular Classification  
Search of PRNP  mutations and M/V polymorphism at codon 129 were carried out on DNA 
extracted from blood specimens or from frozen brain tissues, according to standard methods. PrP
Sc 
typing was determined on brain homogenates obtained from different areas, after treatment with 
proteinase-K for 1 h at 37 °C. The immunoblot profile of PrP
sc was classified as type 1 or type 2, as 
previously described [3]. Each sCJD case was classified according to the genotype (M or V) at codon 
129, the PrP
Sc type, and the neuropathological phenotype: 76 subjects were MM1, 7 MV1, 4 MM2,  
20 MV2, and 20 VV2. 
2.3. CSF Protein Analysis  
CSF samples were stored at −80 °C prior to analysis. The 14-3-3 protein was assayed by 
immunoblotting, following SDS-PAGE. For this purpose, 10 μL of CSF was separated by SDS-PAGE 
and transferred to PVDF membranes (Immobilon P; Millipore) [14]. Each gel included 10 and 20 pg of 
recombinant 14-3-3 γ, CSF from definite sCJD cases, and normal controls. Membranes were incubated 
with anti-14-3-3 β polyclonal rabbit IgG cross-reacting with γ,  ε,  ζ, and η isoforms (Pan 14-3-3 
antibody SC-629; Santa Cruz Biotechnology), at 1:500 dilution, then incubated with anti-rabbit 
immunoglobulin at 1:3,000 dilution. The reaction was revealed by an enhanced chemiluminescence 
system (ECL; Amersham). The presence of the 14-3-3 band was scored by two independent observers 
and classified as negative or positive based on comparison with positive controls and recombinant  
14-3-3 protein. Total tau protein, phosphotau181 and Aβ1-42 were measured using enzyme 
immunoassays (Innogenetics, Ghent, Belgium). For total tau a threshold of 1300 pg/mL was selected 
as the cut-off value, with values higher than 1300 pg/mL being considered specific for sCJD [21]. Int. J. Mol. Sci. 2011, 12                 
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2.4. Statistical Analyses 
Statistical analyses were done using the program Excel (Microsoft). To compare continuous 
variables (presented as mean  ± SD) between two groups, the unpaired samples t test was applied. The 
Chi-square test and the Fisher’s exact test were applied to categorical variables. 
3. Results  
3.1. Molecular, Demographic and Clinical Characteristics of sCJD Patients 
MM1 subjects accounted for 59% of all sCJD cases and had mean disease duration of 6 months 
with a range of 2 weeks–17 months. In 90% of MM1 cases the clinical features were consistent with 
the ‘classic’ or Heidenhain’s phenotypes. Within the MV1 subtype, conventionally grouped with MM1 
subjects, 4 out 7 patients had relatively long disease duration and an atypical clinical course. 
Conversely, MV2 and VV2 subtypes were similar as age at disease onset (67 ± 8 and 65 ± 8 years, 
respectively), but had different disease duration (MV2, 17.4 ± 10 and VV2, 7.4 ± 5.5 months;   
p < 0.002). Most VV2 patients displayed a subacute cerebellar syndrome rapidly complicated by 
dementia, while patients of the MV2 subtype, showed a more heterogeneous disease phenotype at 
presentation, with cerebellar and/or extrapyramidal/pyramidal signs, or cognitive impairment. The 4 
subjects classified as MM2 cortical subtype (MM2C) had a younger age at onset (60 ± 4), a duration of 
11 ± 9 months, and a clinical course characterized by behavioral changes/cognitive disturbances. The 
lag of time between disease onset and CSF analysis ranged from 2.5 ± 2.9 months in MM1 cases to  
7 ± 5 in MV2 subjects. fCJD cases were younger at onset and had a disease phenotype mimicking 
‘classic’ sCJD (Table 1). 
Table 1. Molecular and demographic data of sporadic Creutzfeldt-Jakob disease (sCJD) 
and familial CJD (fCJD) subjects. 
Molecular  
subtype 
Relative  
% 
Gender 
F/M 
Mean age 
(years) 
Time from disease onset  
to lumbar puncture 
(months) 
Disease  
duration  
(months) 
MM-1 (n = 76)  59  33/43 
70 ± 8 
(53–99) 
2.5 ± 2.9 
(0.5–18) 
6 ± 5 
(0.5–27) 
MV-1 (n = 7)  6  5/2 
70 ± 7 
(52–76) 
4.1 ± 2.7 
(1–9) 
10.5 ± 4 
(6–17) 
MM-2 (n = 4)  3  2/2 
60 ± 4 
(54–62) 
5.8 ± 3 
(4–11) 
11 ± 9 
(4–18) 
MV-2 (n = 20)  16  4/16 
67 ± 8 
(53–81) 
7 ± 5 
(2–24) 
17.4 ± 10 
(7–48) 
VV-2 (n = 20)  16  11/9 
65 ± 8 
(54–79) 
4.2 ± 3.2 
(1–13) 
7.3 ± 5.5 
(3–25) 
fCJD (n = 5)  -  3/2 
57 ± 10 
(47–73) 
2 ± 1 
5.8 ± 1.4 
(4–8) Int. J. Mol. Sci. 2011, 12                 
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3.2. CSF 14-3-3 Protein Assay and Tau Protein Levels 
The 14-3-3 assay was positive in 96% of sCJD patients and in 100% of fCJD subjects. On the 
contrary, the 14-3-3 tested positively in 30% of AD and 13% of FTD. An upper cut-off threshold of 
4000 pg/mL was selected for tau, since all reported values in non-sCJD are below this value. In 54% of 
sCJD subjects and in all fCJD cases, tau levels were over 4000 pg/mL. In contrast, in AD and FTD 
levels of tau protein were 898 ± 522 and 287 ± 194 pg/mL, respectively (Table 2). Statistical analyses 
showed that sCJD cases were significantly different from AD and FTD (AD vs sCJD p < 0.001; FTD 
vs sCJD p < 0.0001), but no differences were observed between AD and FTD. Therefore, in patients 
with dementia, in whom a differential diagnosis is required, 14-3-3 protein positivity and tau CSF 
levels over 1300 pg/mL tau represent reliable markers for sCJD.  
Table 2. Results of CSF 14-3-3 assay and tau protein levels in sCJD, fCJD, Alzheimer’s 
disease (AD), frontotemporal dementia (FTD), and controls. 
Subjects 
14-3-3 Protein 
positive 
Tau protein levels (pg/mL) 
mean ± SD
Subjects with 
tau protein >4000 pg/mL
sCJD (n = 127) 
fCJD (n = 5) 
122 (96%) 
5 (100%) 
3305 ± 1096 
4000 
79 
5 
FTD (n = 15)  2 (13%)  287 ± 194  - 
AD (n = 7)  2 (28%)  898 ± 522  - 
CTR (n = 15)  -  188 ± 46  - 
3.3. CSF 14-3-3 Protein and Tau Protein Levels in Distinct sCJD Subtypes 
As previously observed, the disease characteristics of different sCJD subtypes are highly variable, 
including cases with RPD and/or ataxic forms, and cases with slowly progressive cognitive decline 
and/or behavioral changes. Accordingly, we assessed 14-3-3 positivity and tau levels in each distinct 
subtype and we compared the results with other dementias. As expected, the 14-3-3 assay performed 
differently among different subtypes. While all MV1 and VV2 cases had a positive test, within the 
MM1 subtype, positivity was seen in 98.5% of the subjects, a value decreasing to 90% in MV2, and to 
50% in MM2 subtype (Table 3). Among sCJD subtypes, variability was also observed for CSF tau 
levels (Table 3). Tau levels were below the 1300 pg/mL threshold in 2 MM1 subjects out of 76  
(1 being also 14-3-3 negative), 1 MV1 case out of 7, and 5 MV2 patients out of 20 (one sample was 
14-3-3 negative). The lowest frequency of 14-3-3 positivity (50%) was observed in the MM2C 
subtype, whereas 100% positivity was seen in the VV2 subtype. In 5 sCJD subjects, 3 MV2 and 2 
MM2, who had tau levels below 1300 pg/mL at first CSF analysis, a second spinal tap was required for 
diagnosis (Table 4).  Int. J. Mol. Sci. 2011, 12                 
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Table 3. 14-3-3 assay and levels of tau protein in sCJD subtypes and fCJD vs other dementias. 
Molecular type 
14-3-3 
Positivity 
Tau protein 
> 4000 pg/mL 
Tau protein 
1300<  >4000 
Tau protein 
< 1300 pg/mL 
MM-1 (n = 76)  75 (98.5%)  59 (78%) 
15 (20%) 
(Mean: 2546 ± 870) 
(Range: 1443–3864) 
2 (2.6%) 
(230,1272) 
MV-1 (n = 7)  7 (100%)  2 (28%) 
4 (57%) 
(Mean: 2270 ± 1120) 
(Range: 1478–3062) 
1 (14%) 
(650) 
MM-2 (n = 4)  2 (50%)  1 (25%)  1 (25%) 
2 (50%) 
(609,445) 
MV-2 (n = 20)  18 (90%)  4 (20%) 
11 (55%) 
(Mean: 2211 ± 1068) 
(Range: 1628–3792) 
5 (25%) 
(Mean 892 ± 264) 
VV-2 (n = 20)  20 (100%)  13 (65%) 
7 (35%) 
(Mean: 3433 ± 818) 
(Range: 1628–3897) 
- 
fCJD (n = 5)  5 (100%)  5  -  - 
AD (n = 7)  2 (30%)  -  1507,1663  529 ± 336 
FTD (n = 15)  2 (13%)  -  -  287 ± 194 
CTR (n = 15)  -  -  -  188 ± 46 
Table 4. sCJD patients with tau levels below 1300 pg/mL at first spinal tap. 
Molecular 
subtype 
First spinal tap  Lag between 
spinal taps 
(months) 
Second spinal tap 
14-3-3 Protein 
Tau protein 
(pg/mL) 
14-3-3 Protein 
Tau protein 
(pg/mL) 
MM-2 +/- 609  2  + 767 
MM-2 + 445  4  + 2560 
MV-2 + 507 15  + 3792 
MV-2 + 1040 3  + 1925 
MV-2 + 676  1  + 2659 
3.4. CSF Phosphotau181 and Aβ1-42 in sCJD Subtypes and Other Neurodegenerative Dementias 
To investigate whether the CSF conventional diagnostic markers of neurodegenerative dementias 
might be helpful for sCJD diagnosis, we also evaluated phosphotau181 and Aβ1-42 levels in selected 
sCJD cases. In sCJD, despite the elevated CSF tau levels, the mean levels of phosphotau181 were  
46 ± 22 pg/mL, and the ratio phosphotau181/tau was 0.014. On the contrary, phosphotau181 levels were 
105 ± 47 pg/mL in AD (phosphotau181/tau, 0.17), and 37 ± 17 pg/mL in FTD (phosphotau181/tau, 0.16), 
values tenfold higher as compared to sCJD (Table 5). Int. J. Mol. Sci. 2011, 12                 
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Table 5. Cerebrospinal fluid (CSF) levels of tau and phosphotau181 in subjects with sCJD, 
AD, FTD and encephalitis. 
Subjects 
Tau protein pg/mL 
mean ± SD 
PhosphoTau 181 pg/mL 
mean ± SD 
PhosphoTau 181/ Tau 
All  sCJD (n = 127)  3305 ± 1096  46 ± 22  0.014 
MM-1 (n = 76)  3456 ± 972  42 ± 17  0.019 
MV-1 (n = 7)  2772 ± 1394  48 ± 27  0.034 
MM-2 (n = 4)  1455 ± 1701  28 ± 4.4  0.049 
MV-2 (n = 20)  2211 ± 1068  53 ± 17  0.038 
VV-2 (n = 20)  3433 ± 817  56 ± 40  0.016 
AD (n = 7)  898 ± 522  105 ± 47  0.17 
FTD (n = 15)  287 ± 194  37 ± 17  0.16 
CTR (n = 15)  188 ± 46  29 ± 8  0.16 
Encephalitis (n = 6)  1814 ± 163  35 ± 11  0.019 
 
Figure 1. Phosphotau181/tau ratio in sCJD subtypes, FTD, AD, and herpes encephalitis. 
 
Phosphotau181 values and phosphotau181/tau ratio did not significantly differ among distinct sCJD 
subtypes, whereas each subtype was different from AD (p < 0.001) and FTD (p < 0.002). Therefore, 
the use of CSF phosphotau181/tau ratio encourages its use as a sCJD marker (Figure 1). We next 
assessed the phosphotau181/tau ratio in the CSF of patients with herpetic encephalitis and we compared 
values with those seen in sCJD subjects. As expected, tau protein levels resulted elevated in subjects 
with encephalitis and the phosphotau181/tau ratio was low (0.019), thus overlapping data obtained in 
sCJD. These findings confirm that post-translation modifications of tau protein occur in AD and FTD, 
but not in sCJD. We also determined the levels of CSF Aβ1-42 in selected sCJD subjects of all available 
subtypes, AD and FTD. The rationale for doing so is the fact that Aβ1-42 is now included among the 
CSF markers supportive for AD diagnosis and staging. Interestingly, Aβ1-42 levels resulted 
significantly higher in all sCJD subtypes as compared to values obtained in AD and FTD. Int. J. Mol. Sci. 2011, 12                 
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Additionally, we calculated the ratio Aβ1-42/phosphotau181 (Figure 2), a marker highly suggestive for 
AD diagnosis when values are below 6.5 [22]. In contrast to AD and FTD, the above ratio was higher 
than 6.5 in all sCJD subtypes, albeit in several subjects of all subtypes, except MM2, individual values 
were below 6.5. 
Figure 2. Aβ1-42/ phosphotau181 ratio in sCJD subtypes, FTD, AD, and encephalitis.  
 
4. Conclusions 
The trend, in present-day searches for neurodegeneration biomarkers, is not just to find a single 
protein as an indicator of a distinct disorder, but rather to assess a panel of reliable biomarkers, whose 
combined expression will tend towards 100% sensitivity coupled with 100% specificity, a major goal 
in current research. To date, two main strategies have been pursued for the evaluation of CSF 
biomarkers in neurodegenerative disorders. These include the search for surrogate markers, to monitor 
the state and stage of disease on one hand, and the detection of proteins primarily involved in disease 
pathogenesis on the other hand. In sCJD, a positive CSF 14-3-3 assay is highly supportive of   
intra vitam diagnosis, provided there is an appropriate clinical setting, i.e. the presence of a typical 
EEG pattern and the occurrence of distinctive MRI changes. In sCJD patients included in our 
retrospective study, CSF 14-3-3 protein was positive in 96% of cases, while 100% of fCJD cases tested 
14-3-3 positive. However, 30% of AD cases and 13% of FTD subjects also tested positive. These 
results are substantially in keeping with those reported in other investigations and further indicate that 
14-3-3 is a highly sensitive marker with a low specificity profile. However, the absence of a standard 
protocol for 14-3-3 protein detection, whether qualitative or quantitative, may result in arbitrary 
determination, thus explaining the consistent variability among different studies [23,24]. Attempts to 
overcome this limitation have been provided by Gmitterova et al., who performed a quantitative 
ELISA analysis of 14-3-3 protein in distinct sCJD subtypes. In the foregoing study, the highest levels 
of 14-3-3 protein were observed in VV2, MM1 and MV1 subtypes, which are characterized by a rapid 
progression, while CSF 14-3-3 expression was significantly lower in MM2C and MV2 subtypes with Int. J. Mol. Sci. 2011, 12                 
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long disease duration and atypical course [25]. Castellani et al. reached similar conclusions, 
confirming that the molecular subtype should be taken into account when interpreting results of the  
test [26]. 
Our results on the assessment of tau levels across distinct molecular subtypes, show tau levels 
below the conventional threshold of 1300 pg/mL in a high proportion of MM2C and MV2 patients, in 
whom a repeated lumbar puncture was necessary. This confirms that in such cases, sCJD diagnosis 
might be less than simple and requires a follow-up of CSF markers as well as the determination of the 
codon 129. Different groups use arbitrary cut-off levels of tau, spanning from 1000 pg/mL to   
1400 pg/mL. As shown in the present study, levels of tau protein higher than 1300 were found in sCJD 
only, with the exception of a single rapidly evolving AD case having tau levels of 1355 pg/mL. In 
contrast, in all subjects with FTD, tau levels were below the standard values [27]. The sensitivity and 
specificity of additional CSF markers, other than 14-3-3 protein and tau protein across sCJD subtypes, 
has never been previously assessed. Given the diagnostic difficulties encountered with MM2C and 
MV2 subtypes, we determined the diagnostic accuracy of Aβ1-42 or phosphotau181 in differentiating 
sCJD from other degenerative dementias. We found that the ratio phosphotau181/tau significantly 
differentiated all sCJD subtypes from AD and FTD. Therefore, we propose a diagnostic flow-chart 
which might be followed in a clinical setting of dementia in order to differentiate sCJD from non-sCJD 
forms, including AD and FTD (Figure 3). 
Figure 3. Chart for diagnosis of sCJD versus FTD and AD. 
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